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Leukemic stem cells (LSCs) reside within bone marrow niches that maintain their relatively
quiescent state and convey resistance to conventional treatment. Many of the microenviron-
mental signals converge on RAC GTPases. Although it has become clear that RAC proteins
fulfill important roles in the hematopoietic compartment, little has been revealed about the
downstream effectors and molecular mechanisms. We observed that in BCR-ABL-
transduced human hematopoietic stem/progenitor cells (HSPCs) depletion of RAC2 but not
RAC1 induced a marked and immediate decrease in proliferation, progenitor frequency,
cobblestone formation and replating capacity, indicative for reduced self-renewal. Cell cycle
analyses showed reduced cell cycle activity in RAC2-depleted BCR-ABL leukemic cobble-
stones coinciding with an increased apoptosis. Moreover, a decrease in mitochondrial
membrane potential was observed upon RAC2 downregulation, paralleled by severe mito-
chondrial ultrastructural malformations as determined by automated electron microscopy.
Proteome analysis revealed that RAC2 specifically interacted with a set of mitochondrial
proteins including mitochondrial transport proteins SAM50 and Metaxin 1, and interactions
were confirmed in independent co-immunoprecipitation studies. Downregulation of SAM50
also impaired the proliferation and replating capacity of BCR-ABL-expressing cells, again
associated with a decreased mitochondrial membrane potential. Taken together, these
data suggest an important role for RAC2 in maintaining mitochondrial integrity.
Introduction
Hematopoiesis is a hierarchical process, initiated by hematopoietic stem cells (HSCs) that re-
side within specialized regions of the bone marrow, termed the niche [1,2]. A constant crosstalk
between an HSC and its microenvironment provides signals that maintain the HSC in a quies-
cent state and regulate its proliferation and differentiation, crucial both for the homeostasis of
the hematopoietic system and stress hematopoiesis [3–9]. The hierarchical organization of the
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healthy hematopoietic system is to a certain extent maintained upon malignant transforma-
tion. Mouse xenograft models have shown that leukemic cells have a phenotypic hierarchy,
and that only a subpopulation of malignant cells is able to recapitulate the disease in recipient
animals [10,11]. This ability to initiate, maintain and serially propagate leukemia in vivo is the
hallmark property of leukemic stem cells (LSCs) [10]. Similarly to their healthy counterparts,
LSCs are also found within specialized bone marrow niches, and they utilize this microenviron-
ment to maintain a relatively quiescent state. Consequently, LSCs are able to escape the cyto-
toxic effects of chemotherapy and give rise to the relapse of the disease, which occurs in a large
majority of acute myeloid leukemia (AML) patients [12,13]. In chronic myeloid leukemia
(CML), the dormant LSCs are largely independent on the BCR-ABL signaling and therefore
cannot be eradicated by BCR-ABL tyrosine kinase inhibitors (TKIs), so that disease often reoc-
curs upon discontinuation of TKI treatment [14–17]. It is postulated that the disruption of the
LSC-niche interactions leading to the egress of LSCs from their microenvironment would facil-
itate targeting of those cells [18,19]. Therefore, identification of the key components of the LSC
niche will be instrumental for the ultimate eradication of leukemia.
Proteins of the RAC family have been identified as crucial mediators of the interactions be-
tween hematopoietic stem cells (HSCs) and their microenvironment [20,21]. These small
GTPases act as molecular switches, cycling between an inactive GDP-bound state and an active
state in which they are GTP-bound. RACs are activated by various signaling events from the
cell surface, such as activation of tyrosine kinase receptors, G protein-coupled receptors, and
cell-to-cell contacts. These in turn activate several downstream targets, including cytoskeleton
rearrangements [22–25]. Consequently, RAC proteins have a critical role for the biology of
HSCs, as they have been implicated in such processes as migration, homing and retention of
HSCs in the bone marrow [20,26,27]. The RAC family consists of RAC1, RAC2 and RAC3,
which show tissue-specific expression distribution. RAC1 and RAC2 are both expressed in the
hematopoietic system and despite high sequence homology (90%) both unique and overlap-
ping functions of these two proteins have been proposed in murine hematopoiesis [20,26,28].
Next to its crucial role in normal hematopoiesis, RAC activity has been implicated in the dis-
ease initiation and maintenance in various murine leukemia models, including BCR-ABL and
MLL-AF9-driven transformation [29–32]. In accordance with that, inhibition of RAC activity
has been proven a successful strategy to target primary human AML and CML cells in vitro
and in vivo [29,32,33]. Despite the growing understanding of their role in murine models, our
insight into molecular mechanisms by which RAC proteins contribute to the development of
human leukemia remains limited.
Here, using RNA-interference we observed that BCR-ABL-transduced human hematopoiet-
ic stem/progenitor cells (HSPCs) critically depended on RAC2 for their long-term growth. As-
sessment of the mitochondrial membrane potential in RAC2-depleted cells indicated
mitochondrial dysfunction, which coincided with ultrastructural abnormalities identified in
RAC2-deficient BCR-ABL cells by electron microscopy. Moreover, we performed a proteomics
screen to identify RAC1- and RAC2-specific interaction partners and found several mitochon-
drial proteins to be specifically associated with RAC2, including SAM50 and Metaxin1. We
propose that RAC2 is necessary for the proper mitochondrial function in BCR-ABL-expressing
HSPCs and that inhibiting RAC2 could aid in the targeting of those primitive leukemic cells.
Materials and Methods
Primary cell isolation and culture conditions
Neonatal cord blood (CB) was obtained from healthy full-term pregnancies after informed
consent in accordance with the Declaration of Helsinki from the obstetrics departments of the
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University Medical Centre Groningen (UMCG) and Martini Hospital Groningen, Groningen,
The Netherlands. Donors were informed about procedures and studies were performed with
CB by an information sheet that was read and signed by the donor, in line with regulations of
the Medical Ethical Committee of the UMCG. All protocols were approved by the Medical Eth-
ical Committee of the UMCG. After separation of mononuclear cells with lymphocyte separa-
tion medium (PAA Laboratories), CD34+ cells were isolated using a magnetically activated cell
sorting (MACS) CD34 progenitor kit (Miltenyi Biotech). For the MS5 co-culture experiments,
cells were grown in Gartner’s medium consisting of α-modified essential medium (α–MEM;
Fisher Scientific Europe) supplemented with 12.5% heat-inactivated fetal calf serum (Lonza),
12.5% heat-inactivated horse serum (Invitrogen), 1% penicillin and streptomycin, 2mM gluta-
mine (all from PAA Laboratories), 57.2 μM β-mercaptoethanol (Merck Sharp & Dohme BV)
and 1μM hydrocortisone (Sigma-Aldrich Chemie B.V.). Blast crisis chronic myeloid leukemia
(BC CML) blasts from peripheral blood cells from an untreated patient with BC CML (patient
2007–048, with the t(9;22) translocation) were obtained and studied after informed consent in
accordance with the Declaration of Helsinki, and the protocol was approved by the Medical
Ethical Committee of the UMCG. Donors were informed about procedures and studies per-
formed with AML cells by an information sheet that was read and signed by the donor, in line
with regulations of the Medical Ethical Committee of the UMCG. BC CMLmononuclear cells
were isolated by density gradient centrifugation and CD34+ cells were stained using CD34-PE
antibody (BD Biosciences) and selected by sorting on a MoFLo (DakoCytomation). BC CML
co-cultures were expanded in Gartner’s medium supplemented with 20ng/mL interleukin 3
(IL-3; Gist-Brocades), granulocyte-colony stimulating factor (G-CSF; Rhone-Poulenc Rorer)
and thrombopoietin (TPO; Kirin).
Cell lines and culture conditions
293T embryonic kidney cells (ACC-635 DSMZ) and PG13 packaging cells (ATCC CRL-
10686) were grown in DMEMmedium with 200mM glutamine (BioWhittaker) supplemented
with 10% FSC and 1% penicillin and streptomycin. K562 myelogenous leukemia cells (ACC-
10, DSMZ) and TF-1 erythroleukemic cells (ACC-334, DSMZ) were grown in RPMI medium
with 200mM glutamine (BioWhittaker) supplemented with 10% FCS, and 1% penicillin and
streptomycin, and for TF-1 cells with 5 ng/ml granulocyte-macrophage colony stimulating fac-
tor (GM-CSF; Genetics Institute, Cambridge, MA, USA). MS-5 murine stromal cells (ACC-
441, DSMZ) were grown in αMEM with 200mM glutamine (BioWhittaker) supplemented
with 10% FCS and 1% penicillin and streptomycin.
Retro- and lentivirus generation and transduction
Stable PG13 producer cell lines of BCR-ABL retroviral constructs were generated and used as
published previously [34]. Supernatants from the PG13 cells were harvested after 8 to 12 hours
of incubation in human progenitor growth medium (HPGM; Cambrex) before the retroviral
transduction rounds and passed through 0.45 μM filters (Sigma-Aldrich). Before the first trans-
duction round, CD34+ CB cells were pre-stimulated for 48 hours in HPGM supplemented with
100ng/ml stem cell factor (SCF), FLT3 Ligand (Flt3L; both from Amgen) and TPO. Three
rounds of transduction were performed on retronectin-coated 24-well plates in the presence of
the same cytokines as for pre-stimulation and 4 μg/mL polybrene (Sigma-Aldrich). During the
last round of retroviral transduction with BCR-ABL, lentiviral shRNA particles were also
added as described below.
Short hairpin RNA (shRNA) sequences targeting RAC1 (AACCTTTGTACGCTTTGCTCA),
RAC2 (AAGGAGATTGACTCGGTGAAA), or SAM50 (GCGGAATGTTGGTACCCATTG) were
Leukemic Stem Cells Specifically Depend on RAC2
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ligated into pHR’trip vector using AcsI and SbfI restriction sites. For the control, scrambled
(Scr) shRNA sequence was used. 293T embryonic kidney cells were transfected using
FuGENE6 (Roche) with 3 μg pCMV Δ8.91, 0.7 μg VSV-G, and 3 μg of pHR’trip vector con-
structs (shSCR, shRAC1, shRAC2 or shSAM50). After 24 hours medium was changed to
HPGM and after 12 hours supernatant containing lentiviral particles was harvested and either
stored at -80°C or used fresh for transduction of target cells. BCR-ABL-transduced CD34+ CB
cells were subjected to 1 round of transduction with lentiviral particles, together with the last
round of retroviral transduction, in the presence of prestimulation cytokines and 4 μg/mL
polybrene (Sigma) on retronectin-coated 24-well plates. After transduction, transduced green
fluorescent protein (GFP)-positive (indicative of transduction with shRNA-containing vec-
tors), truncated nerve growth factor receptor (NGFR)-positive (indicative of transduction with
BCR-ABL-containing vector) or double-positive cells were sorted on a MoFlo sorter (Dako
Cytomation). BC CML CD34+ cells were transduced as described previously [35]. Briefly,
transductions were performed in 3 consecutive rounds of 8 to 12 hours with lentiviral superna-
tant supplemented with 10% FCS, IL-3, granulocyte-colony stimulating factor (G-CSF; Rhone-
Poulenc Rorer, Amstelveen, The Netherlands) and TPO (20ng/m each) and polybrene (4 μg/
ml) on a retronectin-coated 24-wells plate. After transduction, transduced green fluorescent
protein (GFP)-positive (indicative of transduction with shRNA-containing vectors) were
sorted and used to initiate co-cultures.
For transient retroviral transduction, RAC1 and RAC2 were cloned into MiGR1-Avi-IRE-
S2-EGFP-BirA vector using AgeI and MluI restriction sites. Plasmid RNA was purified using
RNeasy kit (Qiagen) according to manufacturer’s protocol. Retroviral particles were produced
by transfection of embryonic kidney 293T cells. Briefly, 293T cells were cultured in DMEM
(Lonza) supplemented with 10% FCS and 1% P/S in gelatine-coated flasks. The following day,
medium was refreshed and 2–6 hr thereafter cells were (co)transfected with packaging plasmid
pCLampho (3.5 μg) and vector constructs for BirA, Avi-RAC1 orAvi-RAC2 (3.5 μg) in the
presence of FuGENE HD (Promega). After 24 hr medium was changed to RPMI. The next day
retroviral supernatant was collected, passed through 0.45 um filter (Millipore, Amsterdam, The
Netherlands) and directly used for stable transduction. K562 cells (0.5x106) were transduced
with retroviral supernatant of either Avi-RAC1 or Avi-RAC2 or BirA, which served as a con-
trol, in two consecutive rounds together with 4 ug/mL of polybrene (Sigma-Aldrich). After
transduction, GFP positive cells were sorted by Fluorescence-Activated Cell Sorting (FACS)
(MoFlo-Astrios, BeckmanCoulter).
Long-term cultures on stroma, CFC and LTC-IC assay
After sorting, 5x103 BCR-ABL cells were plated onto T25 flask pre-coated with MS5 stromal
cells in 5 mL of Gartner’s medium in duplicate. Co-cultures were kept at 37°C and 5% CO2 and
cells were demi-depopulated weekly for analysis. For the inhibition of Rac activity, NSC2766
(NSC; Calbiochem, VWR, Amsterdam, The Netherlands) was added to the co-culture medium
to the final concentration of 20μM, 40μM or 100μM. For the microscopical evaluation of cob-
blestone cells, 2x103 BCR-ABL cells shSCR (short hairpin scrambled oligonucleotides)- or
shRAC2-transduced were plated into T12.5 flasks pre-coated with stromal MS5 cells in 3 mL
Gartner’s medium. Co-cultures were evaluated daily and images of cobblestones were acquired
on Leica DMIL inverted phase microscope. Images were then opened in CorelDRAW X5 soft-
ware (Corel Software), overlain with a grid and cells forming an individual cobblestone were
counted. CFC assays were performed as previously described [36]. For the LTC-IC assay,
BCR-ABL cells were plated in the range of 2 to 486 cells per well in a 96-well plate using Gart-
ner’s medium. Methylcellulose (StemCell Technologies) supplemented with 20 ng/mL of IL-3,
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20 ng/mL of interleukin-6 (IL-6; Gist-Brocades), 20 ng/mL of G-CSF, 20ng/mL of c-kit ligand
(Amgen), and 6 U/mL of erythropoietin (Epo; Cilag) was added at week 5. Two weeks later,
wells containing CFCs were scored as positive and the LTC-IC frequency was calculated using
L-Calc software (StemCell Technologies).
Mitochondrial mass and membrane potential
Mitochondrial mass was determined by staining the cells with MitoTracker Red FM dye (Life
Technologies) according to the manufacturer’s recommendations. 5x105 cells were incubated
with 20 nMMitoTracker for 30 min at 37°C, washed in PBS, and analyzed by FACS. Mito-
chondrial membrane potential was measured by flow cytometry using hexamethylindodicarbo-
cyanine iodide (DilC1) (Molecular Probes) as described previously [37]. Briefly, 5x105 cells
were incubated with 50 ng/ml DilC1 for 30 min at 37°C, washed twice in PBS, and DilC1 fluo-
rescence was analyzed by FACS.
Electron microscopy
BCR-ABL and shSCR- or shRAC2-double transduced HSPCs were collected after 7 days of co-
culture on stroma, pelleted and subsequently fixed in 2% glutaraldehyde in 0.1 M sodiumcaco-
dylate buffer for 24 h at 4°C. After postfixation in 1% osmiumtetroxide/1.5% potasiumferro-
cyanide (2 hr at 4°C), cells were dehydrated using ethanol and embedded in EPON using
standard procedures [38]. 60nm sections were cut and contrasted using 2% uranylacetate in
methanol followed by Reynolds leadcitrate. Images were taken with a Zeiss Supra55 in STEM
mode at 29 KV using an external scan generator (Fibics) yielding large area scans containing
many cells at 3nm/pixel resolution. Examples of acquired images can be found online (for con-
trol cells: http://figshare.com/s/2de8ed72e8e711e492b606ec4bbcf141; for RAC2-depleted cells:
http://figshare.com/s/9ec695f2e8e311e492bb06ec4b8d1f61). 131 control cells and 139
shRAC2-transduced cells were analyzed for the presence of mitochondrial abnormalities.
Pull-down assays and immunoblotting
Sorted K562 cells transduced with BirA, Avi-RAC1 or Avi-RAC2 constructs were pelleted
(each 107 cells) and washed once with cold PBS, in line with our previously published studies
[39]. Cell lysis was performed using an ice-cold buffer consisting of 20 mMHepes pH 7.5 (Life
Technologies), 0.1% Tween 20 (Merck), 0.5% Triton X-100, 150 mMNaCl, 0.1% Sodium deox-
ycholate (all from Sigma-Aldrich) and (freshly added) protease inhibitors (1 mMDTT, 250x
CLAP, 0.1 mM PMSF, all from Sigma-Aldrich) while incubated for 30 min on a rotating wheel
at 4°C. Cell fragments were removed by centrifugation for 15 min at 14.000 rpm at 4°C. Mag-
netic Dynabeads M-280 Streptavidin (Invitrogen) were equilibrated in lysis buffer and 1mg
beads were added to each total cell lysate and incubated overnight at 4°C on a rotating wheel.
Alternatively, immunoprecipitation with anti-SAM50 antibody and Dynabeads Protein A
(invitrogen) was performed according to manufacturer’s instructions. Beads were separated by
the use of a magnetic rack and washed six times in the lysis buffer. In an alternative approach,
sorted K562 cells transduced with GFP-RAC1 or GFP-RAC2 constructs were pelleted (each
10x106 cells) and washed once with cold PBS. Empty vector-GFP-transduced cells were used as
a control. Cell lysate preparation was performed as described above and pull-down assay was
performed using GFP-Trap beads from ChromoTek according to manufacturer’s instructions.
For both streptavidin-based and GFP-based pull-down assays, bound fractions (B) were eluted
from the beads by boiling for 5 min in Leammli sample buffer and ½ of total cell lysate (T),
bound (B) and non-bound (NB) fractions were analyzed by Western blot.
Leukemic Stem Cells Specifically Depend on RAC2
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Western blot analysis was performed according to standard protocols. Antibody against
RAC1 (clone 23A8) and RAC2 were obtained fromMillipore, anti-GFP from Abcam and Stre-
patividin-HRP conjugate antibody from PerkinElmer. Antibodies against SAM50 and Metaxin
1 were kindly provided by Dr. V. Kozjak-Pavlovic (University of Wϋrzburg, Wϋrzburg, Ger-
many). Secondary antibodies (rabbit-anti-mouse-HRP and goat-anti-rabbit-HRP) were pur-
chased from Dako Cytomation and used in 1:3000 dilutions. Binding of antibodies was
detected by chemiluminescence, according to the manufacturer’s instructions (Roche
Diagnostics).
Mass spectrometry analysis
Bound fraction samples for BirA, Avi-RAC1 and Avi-RAC2 were separated on a 4–12%
NuPAGE pre-cast gel (Invitrogen), stained with Coomassie blue G250 and subsequently de-
stained overnight. Gel bands were excised into 9/10 gel slices for in-gel trypsin digestion. Each
slice was further cut into 1 mm pieces and completely destained using 50 mM ammonium bi-
carbonate (ABC) in 50% acetonitrile (ACN). A reduction and alkylation step was performed to
block cysteins. Briefly, 10 mM DTT in 50mM ABC was added to the gel pieces and incubated
for 45 min at 55°C. Next, 55 mM iodoacetamide in 50 mM ABC was added and incubated for
30 min at room temperature. Gel pieces were dehydrated and allowed to dry, after which they
were re-swelled in 10 ng/ul trypsin solution in 40 mM ABC and 10% ACN at 37°C overnight.
Peptides were fully extracted by adding 2% trifluoroacetic acid (TFA) to the gel pieces, pro-
ceeded by extraction with 33% ACN, 1.3% TFA and followed by 66% ACN, 0.7% TFA. Ex-
tracted peptides were combined and then completely dried in a SpeedVac centrifuge. Peptide
mixtures were further processed for mass spectrometry (LC-MS/MS) analysis on a linear ion
trap LTQ-Orbitrap XL (Thermo Scientifics). Two search engines were used: Mascot (version
2.1.04) and X! Tandem (CYCLONE; 2010.12.01.1) Peptide identifications were accepted with a
probability above 90% and proteins were accepted when the probability score was higher than
90% and at least one unique peptide was identified (Scaffold software; version 3.4.9). Identified
proteins were analyzed by DAVID functional annotation tool.
Fluorescent microscopy
N-terminal GFP fusion constructs of RAC1 and RAC2 were cloned into pRRL construct and
lentivial particle generation was performed as described in”Retro- and lentivirus generation
and transduction” section. TF-1 cells were subjected to 1 round of transduction with lentiviral
particles in the presence of 4 μg/mL polybrene (Sigma) on retronectin-coated 12-well plates
and GFP+ cells were sorted on a MoFlo sorter. Cells were then cytospun and fixated and images
were acquired with a Leica SP2 AOBS confocal microscope, 63x objective. Images were ana-
lyzed with ImageJ software.
RNA extraction and Real-time PCR analysis
RAC1 or RAC2 expression was assessed by quantitative real-time PCR (qRT-PCR). Total RNA
was isolated using RNeasy kit (Qiagen) following the manufacturer’s recommendations. After
reverse transcription using M-MuLV reverse transcriptase (Fermentas), according to manufac-
turer’s instructions, aliquots of cDNA were real-time amplified using iQ SYBR Green mix
(Bio-Rad) on a MyIQ thermocycler (BioRad). RAC1 and RAC2 primer sets were obtained
from Invitrogen. Expression was quantified using MyIQ software (Bio-Rad) and RPL27 expres-
sion was used to calculate relative expression levels of investigated genes according to standard
curve method.
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Statistical analysis
All values are expressed as means ± standard deviation (SD). Student’s t test was used for all
comparisons. Differences were considered statistically significant at p<0.05.
Results
Human BCR-ABL transduced cells critically depend on RAC2 signaling
RAC GTPases are necessary for development and maintenance of leukemia in various murine
models, including BCR-ABL-mediated transformation [30–32]. In order to specifically address
the role of either RAC1 or RAC2 in human leukemia, we used shRNA interference strategy.
We designed shRNA sequences that specifically and efficiently targeted mRNA of the designat-
ed RAC protein, with no effect on the expression of others (Fig 1A and S1 Fig). To investigate
the importance of RAC signaling in human leukemic cells, we retrovirally transduced CD34+
CB cells to overexpress the BCR-ABL oncogene. Simultaneously, lentiviral transduction with
shRNA-containing constructs was performed and double-transduced cells were sorted. Strik-
ingly, RAC2-depleted cells reproducibly showed profound growth impairment within the first
weeks of co-culture, which became even more apparent upon replating (Fig 1B and 1C). More-
over, progenitor frequencies in RAC2-depleted co-cultures were markedly reduced (Fig 1D) as
well as of more primitive LTC-IC cells (1:57 vs. 1:11, p = 0.0001; Fig 1E). Notably, none of
these phenotypes was observed in RAC1-depleted cells in which proliferation was comparable
to controls, progenitor frequencies were initially higher and only mildly decreased at later time
points, and LTC-IC frequencies were not significantly different than those of control cells (Fig
1B, 1D and 1E). Next, we investigated the importance of RAC signaling in primary human leu-
kemic cells. To this end, we isolated CD34+ cells from the peripheral blood of a patient diag-
nosed with blast crisis CML (BC CML) and plated them in stromal co-cultures. Plated cells
were allowed to expand and form cobblestones, after which the RAC inhibitor NSC23766
(NSC) was added to the co-cultures in concentrations of 10μM to 40μM. Treatment with RAC
inhibitor resulted in a reduced expansion of BC CML cells in a dose-dependent manner. Co-
cultures treated with 20μM and 40μM concentration of NSC proliferated significantly less al-
ready at week 2 of the co-culture and at week 3 cells treated with 40μMNSC ceased to grow
(Fig 1F). This indicated that primary BCR-ABL-expressing cells are highly dependent on RAC
signaling, which is in direct agreement with our previous findings [40]. Subsequently, we won-
dered whether also primary BC CML cells are dependent more on RAC2 than RAC1 expres-
sion. To address this, we transduced CD34+ BC CML cells with lentiviral shRNA constructs
and achieved efficient and specific downregulation of either RAC1 or RAC2 (S1 Fig). Trans-
duced cells were sorted, plated on stroma and followed for 5 weeks of co-culture. Similarly to
the BCR-ABL-transduced CB cells, primary BC CML cells also showed marked proliferative
disadvantage upon downregulation of RAC2, with RAC1 depletion having little effect (Fig 1G).
Overall, these data suggest that BCR-ABL-transformed cells critically depend on RAC2 for
their proliferation and self-renewal.
RAC2 depletion profoundly impairs expansion of primitive leukemic
cobblestone cells
To gain more insight into the effect of RAC2 depletion on the most primitive, cobblestone-
forming leukemic cells, we performed extensive microscopical evaluation of BCR-ABL-
transformed co-cultures on stroma. Interestingly, early during the co-culture both the number
and appearance of RAC2-depleted cobblestones were not different than of control counterparts
(Fig 2A and 2B). However, apparent from day 6 to 9 shSCR-transduced cobblestones increased
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Fig 1. Human BCR-ABL-transduced HSPCs specifically depend on RAC2, but not RAC1 expression. (A) Cord blood (CB) CD34+ stem/progenitor cells
were co-transduced with a retroviral construct for BCR-ABL and either a control scrambled shRNA vector (shSCR) or with RAC1/RAC2-targeting shRNA
vectors (shRAC1 or shRAC2). Transduced cells were sorted, cultured on stroma for 10 days and used for RNA extraction. Quantitative PCR was performed
to measure RAC1 (left panel) or RAC2mRNA levels (right panel) normalized against RPL27 mRNA. (B) CB CD34+ stem/progenitor cells were co-transduced
with BCR-ABL and either control shSCR or with shRAC1 or shRAC2. 5x103 double-transduced cells were sorted per group and plated on MS5 stromal cells.
Cultures were demi-depopulated on indicated days for analysis and replated as indicated. The cumulative cell growth is shown for a representative
experiment out of 7 independent experiments. (C) Fold reduction of cumulative cell growth of BCR-ABL and shRAC2-double-transduced CD34+ CB cells in
long-term co-culture as described in panel B, normalized to control cells. Cumulative expansion curves of 7 independent experiments are shown. (D)
Suspension cells fromMS5 co-cultures as described in panel B were analyzed for progenitor frequency by CFC assay at week 1 and week 2 of the co-
culture. 104 cells from each co-culture were plated in a CFC assay in methylcellulose in duplicate, and colonies were evaluated 2 weeks after plating. Total
CFC numbers are shown from a representative of 5 independent experiments. Error bars indicate standard deviation. (E) LTC-IC frequencies were
determined in limiting dilution on MS5 stromal cells. After 5 weeks of culture methylcellulose was added and colonies were scored two weeks later. Poisson
statistics were used to calculate LTC-IC frequencies (p = 0.1 for shSCR vs shRAC1 and p = 0.0001 for shSCR vs shRAC2). (F) BC CML CD34+ cells (patient
2007–043) were sorted and plated on MS5 stroma. Cells were allowed to proliferate for 5 days after which RAC inhibitor was added to the following
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in number and in size while shRAC2-transduced cells did not expand (Fig 2A–2C). From day 9
RAC2-deficient cobblestones started to be depleted from the co-culture and disappeared
completely by day 14, suggesting impaired survival of these cells (Fig 2A). Disappearance of
cobblestones during the co-culture and the dramatic decrease in cell counts (Fig 1A and 1B)
suggested that the primitive BCR-ABL cells underwent cell death; therefore Annexin V FACS
analyses were performed on the cobblestone fraction of BCR-ABL-transduced co-cultures.
While the control-transduced cells displayed a low percentage of Annexin V-positivity, this
percentage was significantly increased in RAC2-depleted cells (Fig 2D) suggesting that an in-
creased apoptotic response was part of the RAC2-deficient phenotype. Next, we assessed the ef-
fect of RAC downregulation on the cell cycle status of the leukemic cobblestone cells. Upon
RAC2 depletion, the fraction of cells in the S and G2/M phase of the cell cycle was markedly re-
duced (Fig 2E), which was in accordance with our microscopical observations (Fig 2A–2C).
Depletion of RAC2 causes mitochondrial dysfunction in BCR-ABL-
expressing HSPCs
We next questioned whether mitochondrial dysfunction might underlie the pheneotypes we
observed in our human leukemia models upon RAC2 depletion. The mitochondrial membrane
potential was assessed in human CD34+ CB cells transduced with BCR-ABL and shRAC2 vec-
tors using DilC FACS analysis. Depletion of RAC2 caused a marked decrease in the mitochon-
drial membrane potential in BCR-ABL-transduced HSPCs (Fig 3A). The MitoTracker Red
signal intensity was comparable between the control and RAC2-depleted BCR-ABL cells, sug-
gesting that the mitochondrial mass was not changed (Fig 3B). Moreover, the level of ROS
measured in BCR-ABL HSPCs was also reduced upon RAC2 downregulation, albeit the level
of reduction did not reach statistical significance (Fig 3C). Overall, these results showed that
RAC2 depletion negatively affected mitochondrial membrane potential in BCR-ABL-express-
ing cells, prompting us to investigate whether the ultrastructure of mitochondria was also al-
tered. Therefore, we analyzed shRAC2-transduced BCR-ABL cells by electron microscopy
(EM). We applied automated EM acquisition of large fields of view at high resolution, recently
introduced as “Nanotomy” [38], which allowed an unbiased assessment of a large number of
cells as wells as gaining insight into the ultrastructure of organelles. Analysis of acquired EM
images revealed that RAC2-depleted cells displayed a particular shape of mitochondrial cristae,
which were forming concentric structures very different from the usual, lamellar appearance of
cristae (Fig 3D and 3E). These concentric structures were observed in almost one-third of
RAC2-depleted cells, while only a few of the control cells contained such abnormal mitochon-
dria (Fig 3F). Moreover, an altered mitochondrial structure could be seen in erythroid, myeloid
and megakaryocytic precursors within the RAC2-deficient sample, suggesting that the mito-
chondrial aberrations occurred already in HSPCs and propagated across all the differentiation
lineages (data not shown).
RAC1 and RAC2 interact with distinct sets of proteins
The results of shRNA interference experiments suggested that RAC2 would have specific func-
tions in human leukemic cells crucial for their survival and long-term proliferation, possibly
linked to mitochondria. To further explore these functions in an unbiased way, we performed
concentrations: 10μM, 20μM or 40μM. Co-cultures were demi-depopulated on indicated days for analysis. Cumulative cell count is shown as an average of 3
independent experiments. Error bars represent standard deviation. (G) BC CML CD34+ cells (patient 2007–043) were transduced with either control shSCR
or with shRAC1 or shRAC2. 5x104 transduced cells were sorted per group and plated on MS5 stromal cells; cultures were demi-depopulated weekly for
analysis. Cumulative cell growth is shown as an average of 3 independent experiments. Error bars represent standard deviation. * P<0.05, ** P<0.01.
doi:10.1371/journal.pone.0128585.g001
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Fig 2. Depletion of RAC2 impairs expansion of primitive leukemic cobblestone cells.CB CD34+ stem/progenitor cells were double-transduced with
BCR-ABL and either control scrambled shRNA vector (shSCR) or with RAC2-targeting shRNA vector (shRAC2) and 2X103 double-transduced cells were
plated on MS5 stromal cells, co-cultures were evaluated daily and images of cobblestones we acquired for 14 days (four representative images of each are
shown in A). (B) The total number of cobblestones present in the culture of control or shRAC2-transduced BCR-ABL cells is shown for the indicated time
points. (C) Acquired images of cobblestones were overlaid with a grid and the number of cells per individual cobblestone was counted for control and
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an open-minded proteomics screen to identify specific interaction partners of the two RAC
proteins, using methodology that we successfully used previously to study the complex compo-
sition of the Polycomb Repressive Complex 1 [39]. To this end, we transduced K562 cell line
with retroviral constructs containing Avi-tagged RAC1 or RAC2 as well as biotin ligase that al-
lowed in vivo biotinylation and efficient pull-down of RAC1- or RAC2-associated protein com-
plexes (Fig 4A and 4B), The pull-down fractions were then analyzed by tandem mass
spectrometry to identify RAC1 or RAC2 associated proteins (experimental setup shown in Fig
4A). Consequently, 335 RAC1-specific and 229 RAC2-specific peptides were identified (Fig
4C). GO annotation revealed that while the common interactome of RAC1 and RAC2 com-
prised mainly of cytoskeleton proteins, their specific interaction partners fell into distinct cate-
gories. RAC1 associated with a significant set of plasma membrane proteins, while RAC2
interacted with a group of mitochondrial membrane proteins forming mitochondrial transport
complexes, as well as mitotic spindle proteins (Table 1). Interaction with such different sets of
proteins suggested differential subcellular localization of RAC1 and RAC2. Indeed, when we
transduced TF-1 leukemic cell line with GFP-tagged constructs of either RAC1 or RAC2, we
could observe that while RAC1 was strongly enriched in the plasma membrane, RAC2 was lo-
calized in the cytoplasm and enriched in the perinuclear region (Fig 4D and S1 Movie and S2
Movie).
The RAC2-interacting protein SAM50 is required for long-term
expansion of human BCR-ABL-expressing HSPCs
The proteomics screen identified several mitochondrial transport proteins as interaction part-
ners of RAC2. Two of those proteins, SAM50 and Metaxin 1 function within the SAM com-
plex, involved in incorporation of proteins to the mitochondrial outer membrane, as well as
regulating cristae stability (Fig 5A) [41,42]. We verified the interaction between these two mito-
chondrial proteins and RAC2 using Streptavidin-based and GFP-based pull-down strategies.
In both cases, SAM50 and Metaxin 1 were enriched in the RAC2 pull-down fraction above the
control background levels. Moreover, imunoprecipitation with anti-SAM50 antibody con-
firmed enrichment of RAC2 signal in the SAM50 pull-down fraction (Fig 5B). Subsequently,
we functionally tested the role of SAM50 in human leukemic HSPCs. To this end, we generated
a lentiviral shRNA construct that efficiently downreguated SAM50 (Fig 5C, top panel). Inter-
estingly, this decrease in the protein level of SAM50 was accompanied by a decrease in the lev-
els of RAC2, although less pronounced (Fig 5C, middle panel). Next, we simultaneously
transduced CD34+ CB cells with the retroviral BCR-ABL construct and the lentiviral shRNA-
containing constructs, double-transduced cells were then sorted and plated on stroma for long-
term co-cultures. Similarly to RAC2-depleted cells, SAM50-deficient BCR-ABL HSPCs also
showed a marked proliferative disadvantage in stromal co-cultures and a diminished replating
capacity (Fig 5D). Moreover, the mitochondrial membrane potential of shSAM50-transduced
cells was significantly reduced (Fig 5E and 5F). Taken together, this data suggest that disturbed
interactions between RAC2 and mitochondrial transport proteins cause mitochondrial dys-
function resulting in impaired proliferation and enhanced apoptosis phenotypes observed in
RAC2-depleted human BCR-ABL cells.
shRAC2-transduced cells, for the time points as in panel B. (D) CB CD34+ stem/progenitor cells were double-transduced with BCR-ABL and either control
scrambled shRNA vector (shSCR) or with RAC2-targeting shRNA vectors (shRAC2) and 5x103 double-transduced cells were sorted and plated on MS5
stromal cells. After 10 days of co-culture cobblestone cells were harvested and Annexin V staining was performed to measure apoptosis. The average of
three independent experiments is shown. Error bars represent standard deviation. (E) Cobblestone cells from cultures like described in panel D were
harvested and used for staining in hypotonic PI solution to evaluate cell cycle distribution. The average of three independent experiments is shown. Error
bars represent standard deviation. * P<0.05, ** P<0.01.
doi:10.1371/journal.pone.0128585.g002
Leukemic Stem Cells Specifically Depend on RAC2
PLOSONE | DOI:10.1371/journal.pone.0128585 May 27, 2015 11 / 20
Fig 3. Depletion of RAC2 causesmitochondrial dysfunction in BCR-ABL-expressing HSPCs. (A) 5x103 BCR-ABL and shSCR or shRAC2 double-
transduced cells were sorted and plated on MS5 stromal cells. Suspension cells were harvested after 14 days of co-culture and stained with DilC to measure
changes in mitochondrial membrane potential. Representative FACS plots are shown. Quantification of FACSmeasurements represented as changes in
MFI relative to control is shown below. The average of four independent experiments is shown with standard deviation. (B) Suspension cells from the double-
transduced co-cultures like described in panel A were harvested after 12 days and stained with MitotrackerRed to measure mitochondrial mass. A
representative FACS plot is shown. Quantification of FACSmeasurements represented as MFI relative to control is shown below. Average of three
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independent experiments is shown with standard deviation. (C) Suspension cells from the double-transduced co-cultures (BCR-ABL and shSCR or shRAC2)
were harvested after 12 days and stained with CellROX to measure oxidative stress. A representative FACS plot is shown. Quantification of FACS
measurements represented as MFI relative to control is shown below. Average of three independent experiments is shown with standard deviation. (D)
BCR-ABL and shRNA double-transduced cells expanded in stromal co-cultures for 7 days were harvested, pelleted and embedded in EPON, and ultrathin
sections were analyzed by STEM. Large area scans of high resolution were acquired allowing evaluation of the ultrastructure of mitochondria in large number
of control cells (D) or shRAC2-transduced cells (E), representative images of the abnormalities in the structure of mitochondria are shown). (F) 131 control
and 139 shRAC2-transduced cells were analyzed for the presence of mitochondrial abnormalities (as seen in E) and the cells with aberrant mitochondria
were enumerated. ** P<0.01.
doi:10.1371/journal.pone.0128585.g003
Fig 4. RAC1 and RAC2 interact with distinct sets of proteins. K562 cells were transduced with retroviral constructs containing Avi-tagged RAC1 (Avi-
RAC1) or RAC2 (Avi-RAC2) and BirA biotin ligase, or BirA-only control construct (BirA) sorted, and streptavidin-based pull-down assay was performed.
Bound fractions were then used for mass spectrometry analysis to identify RAC1- or RAC2-specific interaction partners (experimental setup shown in A). (B)
Efficiency of the pull-down assay was assessed byWestern blot detecting Avi-tagged RAC1 and RAC2. T: total cell lysate fraction; B: bound fraction; NB:
non-bound fraction. (C) Mass spectrometry analysis identified 335 RAC1-specific and 229-RAC2-specific peptides using 90% protein/90% peptide
confidence cut-off. (D) Cytospins of GFP-RAC1- or GFP-RAC2-transduced TF-1 cells were analyzed for RAC localization. Syto62 was used to stain
the nucleus.
doi:10.1371/journal.pone.0128585.g004
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Discussion
Although over the past years it has become clear that RAC proteins fulfill important roles in
the hematopoietic compartment, our insight into molecular mechanisms downstream of
RAC1 and RAC2 is still limited. Here, we show that BCR-ABL-transformed human hemato-
poietic stem/progenitor cells (HSPCs) critically depend on RAC2 for their proliferation and
survival, which is linked to maintaining an appropriate mitochondrial integrity and mitochon-
drial membrane potential. RAC2 specifically interacted with a set of mitochondrial proteins in-
cluding SAM50 and Metaxin1, and downregulation of SAM50 also impaired the proliferation
and replating capacity of BCR-ABL-expressing cells, again associated with a decreased mito-
chondrial membrane potential.
Our data are in line with studies on the role of RAC GTPases in murine leukemia models
that identified the importance of those proteins for the establishing and maintenance of the dis-
ease [29–33,43]. In particular, RAC2 was shown to be critical for the development of
BCR-ABL-mediated malignancy [30,44]. This strong dependency was also evident in our long-
Table 1. MS-identified specific interaction partners of RAC1 and RAC2*.
Term Count PValue Genes
RAC1 interactome
GO:0005856 cytoskeleton 41 8.47E-
06
DNAH11, LZTS1, KRT6B, CALD1, SLC38A6, TTLL4, AKAP9, CD2AP, CDSN, LATS2, DNAH5,
VCL, RPA1, CEP250, AVIL, KRT85, EMD, FGD4, NES, KIF12, EPPK1, TANC1, CENPF,
SYNPO2, RACGAP1, EML6, GRM1, JUP, ARPC1B, CCDC6, SYNE2, EPB41L1, CASS4, KIF1B,
LASP1, TPPP, SPTBN2,
GO:0044430 cytoskeletal part 27 9.83E-
04
DNAH11, KRT6B, LZTS1, CALD1, TTLL4, AKAP9, CD2AP, DNAH5, LATS2, CEP250, KRT85,
EMD, KIF12, NES, TANC1, CENPF, RACGAP1, GRM1, EML6, ARPC1B, KIF1B, LASP1, TPPP,
SPTBN2, PLA2G6, SPTB, SPTAN1
GO:0015629 actin cytoskeleton 11 5.20E-
03
JUP, ARPC1B, LASP1, CALD1, AVIL, SPTBN2, SYNPO2, CD2AP, SPTAN1, SPTB, VCL
GO:0070161 anchoring junction 8 1.16E-
02
JUP, CASS4, LASP1, DSP, CDSN, MLLT4, SPTAN1, VCL
GO:0005912 adherens junction 7 2.35E-
02

















KIF23, PCNT, CEP78, DNAH3, DNAH2, AURKB, KIAA1009, MAD2L1BP, NAV1, MAP4, TUBG1,
MAP6, DST, MYH10
GO:0005856 cytoskeleton 23 6.01E-
03
KIF23, PCNT, SSH3, CEP78, MYH2, DNAH3, MYLK2, AURKB, DNAH2, CAPZB, KIAA1009,
CORO1C, SYNE1, MAD2L1BP, NAV1, GOPC, MAP4, TUBG1, MAP6, SEPT6, DST, MYH7B,
MYH10
GO:0005819 spindle 6 1.09E-
02
KIF23, MAD2L1BP, AURKB, TUBG1, MYH10, KIAA1009
GO:0005739 mitochondrion 18 1.86E-
02
ALDH18A1, NOL3, DNM1L, SAMM50, MTX1, MRPS5, IDH3B, NLRX1, PPP1CC, TIMM23, PCK2,





ALDH18A1, DNM1L, SAMM50, MTX1, NLRX1, GK, PPP1CC, TIMM2
*K562 cells were transduced with retroviral constructs containing Avi-tagged RAC1 (Avi-RAC1) or RAC2 (Avi-RAC2) and BirA biotin ligase, or BirA-only
control construct (BirA) sorted, and streptavidin-based pull-down assay was performed. Bound fractions were then used for mass spectrometry analysis to
identify RAC1- or RAC2-speciﬁc interaction partners. GO annotation was performed on the MS identiﬁed proteins and the most signiﬁcant GO terms for
RAC1 and RAC2 are presented in the table.
doi:10.1371/journal.pone.0128585.t001
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Fig 5. RAC2 interaction with mitochondrial transport proteins is required for the long-term expansion of human BCR-ABL-expressing HSPCs. (A)
Schematic representation of the mitochondrial transport complexes and their function. (B) K562 cells transduced with retroviral constructs containing Avi-
tagged RAC2 (Avi-RAC2) and BirA biotin ligase, or BirA-only control construct (BirA) were sorted, and streptavidin-based pull-down assay was performed.
Conversely, immunoprecipitation with anti-SAM50 antibody was performed. Alternatively, K562 cells were transduced with lentiviral GFP-tagged RAC2
(GFP-RAC2) and pull-down assay using GFP-affinity beads was performed. Empty GFP vector-transduced cells were used as a control. Efficiency of pull-
down assay was assessed byWestern blot detecting either SAM50 or Metaxin 1 (Streptavidin and GFP pull-down), or GFP (SAM50 pull-down). T: total cell
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term cultures of BCR-ABL-transduced human HSPCs, where RAC2-, but not RAC1-depleted
cells showed strongly reduced proliferation, reduced progenitor and stem cell frequencies and
a diminished replating capacity. In line with our findings in oncogene-transduced human CB
models, we observed that primary human CB CML cells were also specifically dependent on
RAC2 for their long-term proliferation. Although studies on a wider collection of leukemic
samples are necessary, these results are a first validation that RAC2 is necessary for primary
human BCR-ABL-induced leukemia as well.
Stromal co-cultures model several aspects of the interactions between HSCs and the bone
marrow environment, such as homing, adhesion, retention and long-term proliferation. There-
fore, we utilized this system to gain insight into the dynamics of the phenotype elicited by
RAC2 depletion in human BCR-ABL HSPCs. The initial migration and adhesion to stroma
were not affected, and early RAC2-deficient cobblestones were indistinguishable from their
control counterparts. However, from day 6 onwards the changes in cobblestone size became
apparent, whereby RAC2-depleted cells stopped proliferating and ultimately underwent apo-
ptosis. This is in agreement with the previous reports from murine models, in which loss of
Rac2 prevented the development of BCR-ABL-initiated leukemia by increasing apoptosis of
LSCs, rather that altering their interactions with the microenvironment [32]. Recently, Niebor-
owska-Skorska et al. showed that RAC2 altered mitochondrial membrane potential and elec-
tron flow through mitochondrial respiratory chain (MRC) complex III. Consequently, high
levels of reactive oxygen species were generated that were responsible for genomic instability of
CML cells and progression to the blast crisis. This effect was counteracted by either knockdown
of RAC2 or pharmacological targeting of RAC activity with small molecule inhibitor [44]. In
our experiments we observed a significant decrease in mitochondrial membrane potential in
RAC2-deficient BCR-ABL cells, which together with the unchanged mitochondrial mass was
indicative for defective functioning of mitochondria. Moreover, upon RAC2 downregulation,
ROS levels within the BCR-ABL-transduced cells decreased, which is in agreement with previ-
ous findings [44]. These functional changes were paralleled by an altered ultrastructure of mi-
tochondria in RAC2-deficient BCR-ABL cells. In shRAC2-transduced cells, mitochondrial
cristae displayed a particular, circular shape, which was almost completely absent from the
control cells. This aberrant shape of cristae was previously found to be associated with mito-
chondrial dysfunction [41,42,45,46]
Murine knock-out models have showed that despite the very high amino acid sequence ho-
mology, RAC1 and RAC2 have non-redundant functions in hematopoietic cells, which could
be explained at least in part by the differences in the C-termini of the two proteins leading to
their distinct subcellular distribution in murine neutrophils [47]. The main function of RAC
GTPases is traditionally associated with cytoskeleton rearrangements and thus processes such
as regulation of cell shape, migration and adhesion [27,28,48]. Accordingly, the common part
of the interactome identified in our proteomics screen comprised of cytoskeleton proteins. In
agreement with the microscopical observation that RAC1 localized in the plasma membrane,
RAC1-specific interaction partners were GO annotated as anchoring junction proteins.
lysate fraction; B: bound fraction; NB: non-bound fraction. (C) K562 cells transduced with the control scrambled shRNA vector (shSCR) or with the
SAM50-targeting shRNA vector (shSAM50) were sorted and used for Western blot analysis to determine SAM50 protein levels. The quantification of protein
expression normalized to control is indicated above each lane. (D) CB CD34+ stem/progenitor cells were double-transduced with BCR-ABL and either control
shSCR or with shSAM50. 5*103 double-transduced cells were sorted per group and plated on MS5 stromal cells. Cultures were demi-depopulated on
indicated days for analysis and replated where indicated. Cumulative cell growth is shown for two representative experiments of 4 independent experiments.
(E) 5*103 BCR-ABL and shSCR or shSAM50 double-transduced cells were sorted and plated on MS5 stromal cells. Suspension cells were harvested after
14 days of co-culture and stained with DilC to measure changes in mitochondrial membrane potential. Representative FACS plots are shown. (F)
Quantification of FACSmeasurements as described in panel (E) represented as changes in MFI relative to control is shown below. Average of four
independent experiments is shown with standard deviation. * P<0.05.
doi:10.1371/journal.pone.0128585.g005
Leukemic Stem Cells Specifically Depend on RAC2
PLOSONE | DOI:10.1371/journal.pone.0128585 May 27, 2015 16 / 20
Conversely, within RAC2-associated complexes several mitochondrial proteins were identified.
This, together with the functional and structural defects of mitochondria in RAC2-depleted
cells prompted us to study in more detail the mitochondrial interactome of RAC2. Three of the
identified RAC2 interactions partners were annotated as mitochondrial membrane proteins
that constitute the mitochondrial transport complexes and two of them, SAM50 and Metaxin
1, are known to interact with each other within the SAM complex [41,42]. Here, we confirmed
that SAM50 and Metaxin 1 co-precipitate with either Avi-tagged or GFP-tagged RAC2. Al-
though some background levels were detected in control precipitates, both SAM50 and
Metaxin 1 were clearly enriched in the RAC2-bound fraction. Moreover, for SAM50 the inter-
action was confirmed by SAM50-specific immunoprecipitation. Also at the functional level,
downregulation of SAM50 in BCR-ABL-expressing HSPCs caused a marked proliferative dis-
advantage and decreased replating capacity, in line with the RAC2-knockdown phenotype. In-
terestingly, knockdown of SAM50 also resulted in slightly reduced levels of RAC2 (Fig 5C). We
speculate that the disruption of RAC2-SAM50 complex by downregulation of SAM50 could
also affect RAC2 stability to some extent, leading to an increase in protein degradation and
consequently slightly lower RAC2 protein levels, although further studies are required to re-
solve this. A decrease in mitochondrial membrane potential was also detected, albeit to a lesser
extent than seen upon RAC2 downregulation. Possibly, this is related to the observation that
RAC2 interacts with more than one mitochondrial membrane protein which would explain
why depletion of RAC2 had a more profound effect on mitochondrial membrane potential
than downregulation of SAM50 alone.
Recent studies showed that depletion of SAM50 and another mitochondrial membrane pro-
tein, mitofilin, resulted in disorganized cristae, morphologically similar to the phenotype we
observed upon RAC2 downregulation [41,45,46]. Interestingly, depletion of these proteins re-
sulted not only in a deficient assembly of the MRC complexes, but it also altered the expression
of several genes involved in oxidative phosphorylation [41]. Deregulated expression of MRC
components has recently been shown to be characteristic for the LSCs in CML chronic phase,
when compared with normal HSCs [49]. The altered expression pattern indicated an increased
level of oxidative phosphorylation in CML LSCs cells that could reflect their increased prolifer-
ation rate [49].
In conclusion, we propose that the active metabolic state of BCR-ABL-expressing cells ren-
ders them highly dependent on the proper functioning of mitochondria and that mitochondrial
dysfunction caused by RAC2 downregulation results in depletion of these cells from the in
vitro cultures. Although more experiments are needed to determine the exact molecular mech-
anisms, the interaction between RAC2 and mitochondrial transport proteins identified here
provides a intriguing novel link between RAC2 and mitochondrial morphology and function.
Supporting Information
S1 Fig. (A) Cord blood (CB) CD34+ stem/progenitor cells were transduced with control scram-
bled shRNA vector (shSCR) or with RAC1/RAC2-targeting shRNA vectors (shRAC1 or
shRAC2), sorted, cultured for 10 days on stroma and used for RNA extraction. Quantitative
PCR was performed to measure RAC1 (left panel) or RAC2 mRNA levels (right panel) normal-
ized against RPL27 mRNA. Alternatively, cells were used for Western blot analysis to deter-
mine RAC1 or RAC2 protein levels. The quantification of protein expression normalized to
control is indicated above each lane. (B) BC CML CD34+ stem/progenitor cells were trans-
duced with control scrambled shRNA vector (shSCR) or with RAC1/RAC2-targeting shRNA
vectors (shRAC1 or shRAC2), sorted, cultured for 10 days on stroma and used for RNA extrac-
tion. Quantitative PCR was performed to measure RAC1 (top panel) or RAC2 mRNA levels
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